Krystal Biotech, Inc. Net Income
Krystal Biotech, Inc. (KRYS) reported Net Income of $54.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-03
- Krystal Biotech, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $54.77M, a 42.87% increase year-over-year.
- Krystal Biotech, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $55.93M, a 56.53% increase year-over-year.
- Krystal Biotech, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $51.40M, a 13.02% increase year-over-year.
- Krystal Biotech, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $79.36M, a 192.00% increase year-over-year.
- Krystal Biotech, Inc. net income (loss) attributable to parent for fiscal 2025 was $204.83M, a 129.74% increase from fiscal 2024.
- Krystal Biotech, Inc. net income (loss) attributable to parent for fiscal 2024 was $89.16M, a 715.58% increase from fiscal 2023.
- Krystal Biotech, Inc. net income (loss) attributable to parent for fiscal 2023 was $10.93M.
- Krystal Biotech, Inc. net income (loss) attributable to parent for fiscal 2022 was -$139.97M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $54.77M 10-Q · filed 2026-08-03 | $110.70M 10-Q · filed 2026-08-03 | $162.10M derived: sum of 3 quarters · filed 2026-08-03 | $241.47M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $55.93M 10-Q · filed 2026-08-03 | $107.33M derived: sum of 2 quarters · filed 2026-08-03 | $186.70M derived: sum of 3 quarters · filed 2026-08-03 | $225.03M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $51.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $130.76M derived: sum of 2 quarters · filed 2026-02-17 | $169.10M derived: sum of 3 quarters · filed 2026-08-03 | $204.83M 10-K · filed 2026-02-17 |
| 2025-09-30 | $79.36M 10-Q · filed 2025-11-03 | $117.70M derived: sum of 2 quarters · filed 2026-08-03 | $153.43M 10-Q · filed 2025-11-03 | $198.91M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $38.33M 10-Q · filed 2026-08-03 | $74.07M 10-Q · filed 2026-08-03 | $119.55M derived: sum of 3 quarters · filed 2026-08-03 | $146.72M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $35.73M 10-Q · filed 2026-08-03 | $81.21M derived: sum of 2 quarters · filed 2026-08-03 | $108.39M derived: sum of 3 quarters · filed 2026-08-03 | $123.96M derived: sum of 4 quarters · filed 2026-08-03 |
| 2024-12-31 | $45.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $72.66M derived: sum of 2 quarters · filed 2026-02-17 | $88.23M derived: sum of 3 quarters · filed 2026-02-17 | $89.16M 10-K · filed 2026-02-17 |
| 2024-09-30 | $27.18M 10-Q · filed 2025-11-03 | $42.75M derived: sum of 2 quarters · filed 2025-11-03 | $43.68M 10-Q · filed 2025-11-03 | $52.37M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $15.57M 10-Q · filed 2025-11-03 | $16.50M 10-Q · filed 2025-08-04 | $25.19M derived: sum of 3 quarters · filed 2026-02-17 | $105.94M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $932.00K 10-Q · filed 2025-11-03 | $9.62M derived: sum of 2 quarters · filed 2026-02-17 | $90.37M derived: sum of 3 quarters · filed 2026-02-17 | $57.16M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $8.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $89.44M derived: sum of 2 quarters · filed 2026-02-17 | $56.23M derived: sum of 3 quarters · filed 2026-02-17 | $10.93M 10-K · filed 2026-02-17 |
| 2023-09-30 | $80.75M 10-Q · filed 2024-11-04 | $47.54M derived: sum of 2 quarters · filed 2024-11-04 | $2.24M 10-Q · filed 2024-11-04 | -$29.81M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | -$33.21M 10-Q · filed 2024-11-04 | -$78.51M 10-Q · filed 2024-08-05 | -$110.56M derived: sum of 3 quarters · filed 2025-02-19 | -$140.41M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$45.30M 10-Q · filed 2024-11-04 | -$77.35M derived: sum of 2 quarters · filed 2025-02-19 | -$107.20M derived: sum of 3 quarters · filed 2025-02-19 | -$135.31M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | -$32.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$61.90M derived: sum of 2 quarters · filed 2025-02-19 | -$90.01M derived: sum of 3 quarters · filed 2025-02-19 | -$139.97M 10-K · filed 2025-02-19 |
| 2022-09-30 | -$29.85M 10-Q · filed 2023-11-06 | -$57.96M derived: sum of 2 quarters · filed 2023-11-06 | -$107.92M 10-Q · filed 2023-11-06 | -$129.73M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$28.11M 10-Q · filed 2023-11-06 | -$78.07M 10-Q · filed 2023-08-07 | -$99.88M derived: sum of 3 quarters · filed 2024-02-26 | -$115.47M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$49.97M 10-Q · filed 2023-11-06 | -$71.77M derived: sum of 2 quarters · filed 2024-02-26 | -$87.36M derived: sum of 3 quarters · filed 2024-02-26 | -$103.72M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$21.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$37.40M derived: sum of 2 quarters · filed 2024-02-26 | -$53.76M derived: sum of 3 quarters · filed 2024-02-26 | -$69.57M 10-K · filed 2024-02-26 |
| 2021-09-30 | -$15.59M 10-Q · filed 2022-11-07 | -$31.95M derived: sum of 2 quarters · filed 2022-11-07 | -$47.76M 10-Q · filed 2022-11-07 | -$58.15M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$16.36M 10-Q · filed 2022-11-07 | -$32.17M 10-Q · filed 2022-08-08 | -$42.56M derived: sum of 3 quarters · filed 2023-02-27 | -$52.17M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$15.81M 10-Q · filed 2022-11-07 | -$26.20M derived: sum of 2 quarters · filed 2023-02-27 | -$35.80M derived: sum of 3 quarters · filed 2023-02-27 | -$42.64M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$10.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$19.99M derived: sum of 2 quarters · filed 2023-02-27 | -$26.83M derived: sum of 3 quarters · filed 2023-02-27 | -$32.17M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$9.61M 10-Q · filed 2021-11-08 | -$16.44M derived: sum of 2 quarters · filed 2021-11-08 | -$21.78M 10-Q · filed 2021-11-08 | -$27.14M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$6.83M 10-Q · filed 2021-11-08 | -$12.17M 10-Q · filed 2021-08-09 | -$17.53M derived: sum of 3 quarters · filed 2021-11-08 | -$21.80M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-03-31 | -$5.34M 10-Q · filed 2021-11-08 | -$10.70M derived: sum of 2 quarters · filed 2021-11-08 | -$14.97M derived: sum of 3 quarters · filed 2021-11-08 | -$20.32M derived: sum of 4 quarters · filed 2021-11-08 |
| 2019-12-31 | -$5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$9.63M derived: sum of 2 quarters · filed 2021-03-01 | -$14.98M derived: sum of 3 quarters · filed 2021-03-01 | -$19.09M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$4.27M 10-Q · filed 2020-11-09 | -$9.62M derived: sum of 2 quarters · filed 2020-11-09 | -$13.73M 10-Q · filed 2020-11-09 | -$17.44M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$5.35M 10-Q · filed 2020-11-09 | -$9.46M 10-Q · filed 2020-08-07 | -$13.17M derived: sum of 3 quarters · filed 2020-11-09 | -$15.92M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-03-31 | -$4.11M 10-Q · filed 2020-11-09 | -$7.82M derived: sum of 2 quarters · filed 2020-11-09 | -$10.57M derived: sum of 3 quarters · filed 2020-11-09 | -$12.85M derived: sum of 4 quarters · filed 2020-11-09 |
| 2018-12-31 | -$3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | -$6.46M derived: sum of 2 quarters · filed 2020-03-10 | -$8.74M derived: sum of 3 quarters · filed 2020-03-10 | -$10.89M 10-K · filed 2020-03-10 |
| 2018-09-30 | -$2.75M 10-Q · filed 2019-11-04 | -$5.03M derived: sum of 2 quarters · filed 2019-11-04 | -$7.18M 10-Q · filed 2019-11-04 | -$8.57M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | -$2.28M 10-Q · filed 2019-11-04 | -$4.43M 10-Q · filed 2019-08-05 | -$5.82M derived: sum of 3 quarters · filed 2019-11-04 | -$11.09M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-03-31 | -$2.15M 10-Q · filed 2019-11-04 | -$3.54M derived: sum of 2 quarters · filed 2019-11-04 | -$8.82M derived: sum of 3 quarters · filed 2019-11-04 | -$9.57M derived: sum of 4 quarters · filed 2019-11-04 |
| 2017-12-31 | -$1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$6.67M derived: sum of 2 quarters · filed 2018-11-05 | -$7.42M derived: sum of 3 quarters · filed 2018-11-05 | -$7.92M 10-K · filed 2018-03-12 |
| 2017-09-30 | -$5.27M 10-Q · filed 2018-11-05 | -$6.03M derived: sum of 2 quarters · filed 2018-11-05 | -$6.53M 10-Q · filed 2018-11-05 | -$7.15M derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-06-30 | -$759.00K 10-Q · filed 2018-08-06 | -$1.25M 10-Q · filed 2018-08-06 | -$1.88M derived: sum of 3 quarters · filed 2018-08-06 | -$2.20M derived: sum of 4 quarters · filed 2018-08-06 |
| 2017-03-31 | -$494.00K 10-Q · filed 2018-05-07 | -$1.12M derived: sum of 2 quarters · filed 2018-05-07 | -$1.44M derived: sum of 3 quarters · filed 2018-05-07 | |
| 2016-12-31 | -$627.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$949.00K derived: sum of 2 quarters · filed 2018-03-12 | -$1.15M 10-K · filed 2018-03-12 | |
| 2016-09-30 | -$322.00K 10-Q · filed 2017-11-13 | -$523.00K 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |